subscribeSubscribe
price-trendAsk Us
Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe

Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe
EMA
19 Oct 2023
Share Share
Boundless Bio Announces Agreement with Taiho Oncology to Evaluate LYTGOBI

Boundless Bio Announces Agreement with Taiho Oncology to Evaluate LYTGOBI
BUSINESSWIRE
18 Sep 2023
Share Share
Taiho`s Lytgobi (futibatinib) Receives Approval in Europe

Taiho`s Lytgobi (futibatinib) Receives Approval in Europe
EMA
18 Jul 2023
Share Share
EC Grants Conditional Marketing Authorization for Taiho`s Lytgobi Tablets

EC Grants Conditional Marketing Authorization for Taiho`s Lytgobi Tablets
PR NEWSWIRE
05 Jul 2023
Share Share
Chmp Issues Positive Opinion For Futibatinib For The Treatment

Chmp Issues Positive Opinion For Futibatinib For The Treatment
PR NEWSWIRE
27 Apr 2023
Share Share
Lytgobi Now Available from Onco360 for the Treatment of Adult Patients

Lytgobi Now Available from Onco360 for the Treatment of Adult Patients
BUSINESSWIRE
13 Feb 2023
Share Share
Taiho to Publish in The New England Journal of Medicine for Futibatinib

Taiho to Publish in The New England Journal of Medicine for Futibatinib
PR NEWSWIRE
18 Jan 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
FDA greenlights Otsuka subsidiary`s bile duct cancer drug

FDA greenlights Otsuka subsidiary`s bile duct cancer drug
Zachary Brennan ENDPTS
04 Oct 2022
Share Share
Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR

Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR
PRNEWSWIRE
04 Jun 2020
Share Share